Next Generation Probiotics (NGPs) are live microorganisms identified through advanced techniques like next-generation sequencing and bioinformatics, which, when administered in adequate amounts, confer specific health benefits to the host. Unlike traditional probiotics, such as Lactobacillus and Bifidobacterium, which are often isolated from fermented foods and have broad, non-specific effects, emerging NGPs are typically derived from the human gut microbiota, making them better adapted to the intestinal environment. They are designed for targeted therapeutic applications, addressing specific diseases like inflammatory bowel disease, obesity, diabetes, cancer, and neurodegenerative disorders.
At present, there are a number of promising NGP strains, like Akkermansia muciniphila, Faecalibacterium prausnitzii and Bacteroides fragilis, being identified and studied, demonstrating potential in modulating gut microbiota, enhancing immunity, and producing beneficial metabolites. However, NGPs face challenges like oxygen sensitivity, stringent regulatory requirements, and the need for advanced delivery systems to ensure viability and efficacy.
REVIVEBIO’s proprietary flagship strain, Parabacteroides goldsteinii RV-01 (P. Gold RV-01), is a NGP extensively researched over the past 15 years, exhibiting remarkable potentials in the areas of anti-aging, metabolism enhancement, anti-neuroinflammation and immunity modulation. P. Gold RV-01 has been evaluated for its toxicity, functionality, mechanism, efficacy and safety—it passed GRAS (Generally Recognized As Safe) self-affirmation process by a third-party institute and is currently undergoing USFDA review for FDA GRAS status.